206 related articles for article (PubMed ID: 31242968)
1. Sacubitril/valsartan for heart failure in adults with complex congenital heart disease.
Maurer SJ; Pujol Salvador C; Schiele S; Hager A; Ewert P; Tutarel O
Int J Cardiol; 2020 Feb; 300():137-140. PubMed ID: 31242968
[TBL] [Abstract][Full Text] [Related]
2. Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease.
Lluri G; Lin J; Reardon L; Miner P; Whalen K; Aboulhosn J
World J Pediatr Congenit Heart Surg; 2019 May; 10(3):292-295. PubMed ID: 31084317
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure - A Single Centre Case Series and Call for an International Registry.
Appadurai V; Thoreau J; Malpas T; Nicolae M
Heart Lung Circ; 2020 Jan; 29(1):137-141. PubMed ID: 30686641
[TBL] [Abstract][Full Text] [Related]
4. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
5. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A
J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687
[No Abstract] [Full Text] [Related]
6. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S
Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
8. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
9. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
Pellicori P; Urbinati A; Shah P; MacNamara A; Kazmi S; Dierckx R; Zhang J; Cleland JGF; Clark AL
Eur J Heart Fail; 2017 Jun; 19(6):768-778. PubMed ID: 28244205
[TBL] [Abstract][Full Text] [Related]
10. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
12. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
14. A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial.
Pang Z; Pan C; Yao Z; Ren Y; Tian L; Cui J; Liu X; Zhang L; Chen Y
Medicine (Baltimore); 2021 Apr; 100(16):e25621. PubMed ID: 33879733
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study.
Fusco F; Scognamiglio G; Merola A; Iannuzzi A; Palma M; Grimaldi N; Sarubbi B
Circ Heart Fail; 2023 Feb; 16(2):e009848. PubMed ID: 36458541
[TBL] [Abstract][Full Text] [Related]
16. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
17. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Ibrahim NE; McCarthy CP; Shrestha S; Gaggin HK; Mukai R; Szymonifka J; Apple FS; Burnett JC; Iyer S; Januzzi JL
J Am Coll Cardiol; 2019 Mar; 73(11):1273-1284. PubMed ID: 30898202
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
19. ▼ Sacubitril valsartan for heart failure.
Drug Ther Bull; 2016 Jun; 54(6):66-9. PubMed ID: 27284124
[TBL] [Abstract][Full Text] [Related]
20. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]